Best of ASCO - 2014 Annual Meeting

 

Welcome

Brain Metastases

Central Nervous System Tumors

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A new option in brain-metastases: Hippocampal-sparing whole-brain radiotherapy with simultaneous integrated boost VMAT-IGRT.

Alicia Marin

e13589

A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).

Priya Kumthekar

2070

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

Alexander E. Drilon

2006

Brain metastases as a first site of recurrence in patients on chemotherapy with controlled systemic cancers: An increasingly urgent clinical scenario.

Kaelin O'Connell

e13590

Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.

Mihaela Aldea

2015

Clinical outcomes in patients with melanoma brain metastases at a tertiary cancer center.

William J Phillips

e13586

Effect and utility of targeted and immune therapy as single agent treatment for brain metastases in patients with non-small cell lung cancer.

Hassan Shalabna

e13581

Effect of oligometastatic disease management with stereotactic body radiation therapy on survival in patients with metastatic lung cancer.

Luis E. Raez

e13582

First-line stereotactic radiosurgery combined with systemic targeted and immune checkpoint inhibitor therapy in melanoma patients with newly diagnosed brain metastases.

Thatcher Ross Heumann

e13577

Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.

Benjamin Y. Lu

2066

Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC).

Renata Duchnowska

e13580

Insight into the brain metastasis journey: Initial survey results from patients and caregivers.

Nicole Willmarth

2069

Integrating salvage hypofractionated radiosurgery plus low-dose adjuvant bevacizumab for locally recurrent brain metastasis with high dose irradiation previously.

Yun Guan

e13579

Intraventricular radioimmunotherapy targeting B7H3 for CNS malignancies.

Kim Kramer

e13592

Management of brain metastases in tyrosine kinase inhibitor-treated epidermal growth factor receptor-mutant non-small-cell lung cancer from the perspective of long-term radiation brain damage: A multi-institutional retrospective analysis.

Hongqing Zhuang

e13587

Molecular profiling using the 92-gene assay for tumor classification of brain metastases.

Andrew Jacob Brenner

e13583

NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).

Vinai Gondi

2009

Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.

Yoshitaka Narita

2065

Presenting symptoms and patient prognosticators in neoplastic meningitis: A single institution experience.

Shilpa Ghatnekar

e13593

Real-world outcome analysis of EGFR-mutated lung adenocarcinoma with brain metastases.

Feng-Che Kuan

e13588

Risk factors for synchronous brain metastases: A National Cancer Database analysis.

Catherine R. Garcia

e13591

Single center, open and prospective evaluation of genomic sequencing on cerebro-spinal fluid, brain metastatic lesions and plasma from patients in non-small cell lung cancer with brain metastasis.

Chunhua Ma

e13578

Stereotactic radiosurgery for resected brain metastases: Does the surgical corridor need to be treated?

Siyu Shi

2068

The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases.

Nancy Wang

e13585